These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2462878)

  • 1. Substrate specificity of bleomycin hydrolase.
    Sebti SM; DeLeon JC; Ma LT; Hecht SM; Lazo JS
    Biochem Pharmacol; 1989 Jan; 38(1):141-7. PubMed ID: 2462878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin.
    Lazo JS; Braun ID; Labaree DC; Schisselbauer JC; Meandzija B; Newman RA; Kennedy KA
    Cancer Res; 1989 Jan; 49(1):185-90. PubMed ID: 2461797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleomycin hydrolase activity and cytotoxicity in human tumors.
    Lazo JS; Boland CJ; Schwartz PE
    Cancer Res; 1982 Oct; 42(10):4026-31. PubMed ID: 6179595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic inactivation: a mechanism of human tumor resistance to bleomycin.
    Sebti SM; Jani JP; Mistry JS; Gorelik E; Lazo JS
    Cancer Res; 1991 Jan; 51(1):227-32. PubMed ID: 1703034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleomycin hydrolase activity in pulmonary cells.
    Lazo JS; Merrill WW; Pham ET; Lynch TJ; McCallister JD; Ingbar DH
    J Pharmacol Exp Ther; 1984 Dec; 231(3):583-8. PubMed ID: 6209387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of recombinant human bleomycin hydrolase on bleomycins and engineered analogues revealing new opportunities to overcome bleomycin-induced pulmonary toxicity.
    Crnovcic I; Gan F; Yang D; Dong LB; Schultz PG; Shen B
    Bioorg Med Chem Lett; 2018 Sep; 28(16):2670-2674. PubMed ID: 29730026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Separation of the protective enzyme bleomycin hydrolase from rabbit pulmonary aminopeptidases.
    Sebti SM; Lazo JS
    Biochemistry; 1987 Jan; 26(2):432-7. PubMed ID: 3103681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S10b.
    Mistry JS; Jani JP; Morris G; Mujumdar RB; Reynolds IJ; Sebti SM; Lazo JS
    Cancer Res; 1992 Feb; 52(3):709-18. PubMed ID: 1370650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleomycin hydrolase: molecular cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase family.
    Sebti SM; Mignano JE; Jani JP; Srimatkandada S; Lazo JS
    Biochemistry; 1989 Aug; 28(16):6544-8. PubMed ID: 2477059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cysteine proteinase inhibitors and bleomycin-sensitive and -resistant cells.
    Morris G; Mistry JS; Jani JP; Sebti SM; Lazo JS
    Biochem Pharmacol; 1991 Jun; 41(11):1559-66. PubMed ID: 1710457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification, characterization, and amino acid composition of rabbit pulmonary bleomycin hydrolase.
    Sebti SM; DeLeon JC; Lazo JS
    Biochemistry; 1987 Jul; 26(14):4213-9. PubMed ID: 3117099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms affecting peplomycin sensitivity of Chinese hamster cell lines.
    Ozawa S; Tamura A; Suzuki H; Nishimura T; Tanaka N
    J Antibiot (Tokyo); 1985 Sep; 38(9):1257-65. PubMed ID: 2415503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lidocaine potentiation of bleomycin A2 cytotoxicity and DNA strand breakage in L1210 and human A-253 cells.
    Lazo JS; Braun ID; Meandzija B; Kennedy KA; Pham ET; Smaldone LF
    Cancer Res; 1985 May; 45(5):2103-9. PubMed ID: 2580616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial single-strand DNA damage and cellular pharmacokinetics of bleomycin A2.
    Lazo JS; Schisselbauer JC; Meandzija B; Kennedy KA
    Biochem Pharmacol; 1989 Jul; 38(13):2207-13. PubMed ID: 2472141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells.
    Pei Z; Calmels TP; Creutz CE; Sebti SM
    Mol Pharmacol; 1995 Oct; 48(4):676-81. PubMed ID: 7476893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tallysomycin S10b: experimental antitumor activity and toxicity.
    Schurig JE; Rose WC; Hirth RS; Schlein A; Huftalen JB; Florczyk AP; Bradner WT
    Cancer Chemother Pharmacol; 1984; 13(3):164-70. PubMed ID: 6207948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liblomycin-mediated DNA cleavage in human head and neck squamous carcinoma cells and purified DNA.
    Wassermann K; Zwelling LA; Lown JW; Hartley JA; Nishikawa K; Lin JR; Newman RA
    Cancer Res; 1990 Mar; 50(6):1732-7. PubMed ID: 1689610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of bleomycin hydrolase by an epitope-specific antibody.
    Morris G; Mistry JS; Jani JP; Mignano JE; Sebti SM; Lazo JS
    Mol Pharmacol; 1992 Jul; 42(1):57-62. PubMed ID: 1378925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further characterization of bleomycin-resistant HeLa cells and analysis of resistance mechanism.
    Urade M; Sugi M; Matsuya T
    Jpn J Cancer Res; 1988 Apr; 79(4):491-500. PubMed ID: 2454906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-performance liquid chromatography assay of bleomycin in human plasma and rat hepatocytes in culture.
    Mahdadi R; Kenani A; Pommery N; Pommery J; Hénichart JP; Lhermitte M
    Cancer Chemother Pharmacol; 1991; 28(1):22-6. PubMed ID: 1710176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.